Deprescribing stewardship gives small gain in older inpatients; FDA approves asundexian after stroke; Arrow guidewires and Alaris sets flagged

Listen to this post
read by AI voices · all episodesA Drug Burden Index stewardship bundle raised deprescribing of anticholinergic or sedative drugs at discharge by 5.3 percentage points in 4,827 older inpatients, less than hypothesized, in a trial published Nov. 9.
The Food and Drug Administration (FDA) approved asundexian, the first factor XIa inhibitor, after mild-to-moderate stroke, flagged Arrow guidewires whose coating may embolize and classed a correction of kits with BD Alaris infusion sets as its most serious recall type.
- Research Nov 9, 2026In a stepped-wedge cluster randomized trial in six Australian public hospitals, published Nov. 9 in JAMA Internal Medicine, a Drug Burden Index stewardship bundle raised the share of older inpatients with at least one anticholinergic or sedative drug deprescribed at discharge to 41.4% from 38.1% in the control phase, an adjusted difference of 5.3 percentage points (95% CI 0.1 to 10.6), smaller than hypothesized. The rate fell to 37.0% once the stewardship component ended. Deprescribing recommendations in discharge summaries rose to 23.4% from 14.6%, and in-hospital adverse events were similar across phases.Sources: JAMA Internal Medicine, PubMed
- FDA Nov 9, 2026The Food and Drug Administration (FDA) on Nov. 9 approved Sunharbo (asundexian) 50 mg, the first factor XIa inhibitor, for use with antiplatelet therapy after a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack, after a 26% reduction in ischemic stroke versus placebo in 12,327 adults. Overall major bleeding was similar, but it was increased in patients older than 75 and in the first 90 days. The drug should be withheld at least 24 hours before elective surgery or invasive procedures and is not recommended in moderate or severe hepatic impairment.Source: FDA
- FDA Nov 10, 2026The Food and Drug Administration (FDA) on Nov. 10 posted an early alert on Arrow International hydrophilic-coated guidewires and the pressure-injectable catheters containing them. Teleflex confirmed the coating may swell inconsistently when hydrated with saline, leading to clumping and potential detachment, and hydrophilic polymer emboli may cause thrombosis, ischemia, stroke or death. The company's Nov. 5 letter told customers to stop use, quarantine and return affected product; it reported no serious injuries or deaths.Source: FDA
- FDA Nov 9, 2026The Food and Drug Administration (FDA) on Nov. 9 classified Cardinal Health's correction of Presource kits containing BD Alaris Pump infusion sets, an update to use instructions, as a Class I recall, its most serious type, updating an Oct. 20 early alert. Set performance deviations, most often at rates under 1 mL/h and bolus volumes of 5 mL or less, can cause under- or over-infusion, with critically ill patients among those at highest risk. FDA lists an alternative syringe pump among options; BD reported no serious injuries or deaths as of Aug. 19.Source: FDA
The weekly innovation roundup for hospital medicine, published every Sunday for the week before; every item links to its sources. Latest hospital medicine news · All specialties